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ABSTRACT
This observational retrospective study conducted during an yellow fever (YF) outbreak 
in Sao Paulo, Brazil, in 2017-2018, describes adverse events (AE) following YF vaccination 
of immunocompromised persons. Risks and benefits of vaccination were individually 
evaluated by physicians. AE were assessed by phone call or electronic mail, 14 to 90 days 
after vaccination. Three hundred and eighty one immunocompromised persons received a 
full-dose of YF vaccine. Their age ranged from 1.4 to 89.3 years (median 50.8 years); 53% 
were women; 178 (46.7%) had chronic kidney disease, 78 (20.5%) had immune-mediated 
inflammatory diseases; 94 (24.7%) were using or had recently used immunosuppressive/ 
immunomodulatory drugs. All of them denied previous YF vaccination. We were able 
to contact 341 (89.5%) vaccinees: 233 (68.3%) of them received the YF vaccine from 
BioManguinhos and 108 (31.7%) received the vaccine from Sanofi-Pasteur; 130 (38.1%) 
vaccinees received other vaccines (up to 4) simultaneously with the the YF vaccine, mostly 
hepatitis B (59 vaccinees), pneumococcal polysaccharide 23-valent (46), influenza (43) and 
diphtheria-tetanus (dT, 41). One hundred and eleven vaccinees (32.6%) reported at least one 
AE: 79 (23.2%) presented systemic AE, 44 (12.9%) had local AE and 12 had both, local and 
systemic AE. The most common AE was pain at the injection site (41 persons, 12%), myalgia 
(34; 10%), fever (25; 7.3%) and headache (16; 4.7%). There was no statistically significant 
difference on the AE frequency according to the vaccine producer. There were four severe 
AE: one hospitalization and three deaths, considered not related to the YF vaccine. 
KEYWORDS: Adverse events following immunization. Yellow fever vaccine. 
Immunosuppression. Chronic renal failure. Autoimmune conditions.
INTRODUCTION
 
Yellow fever (YF) urban transmission has been interrupted in Brazil since 1942, 
but sylvatic YF, historically endemic in the Brazilian Amazon and Midwest regions, 
has expanded to the East and South since the early 2000s1. From time to time, YF 
reemerges in the country, producing outbreaks of varied magnitudes and extent. In 
the late 2016, human YF cases were reported in a previously transmission-free area 
in Minas Gerais State, in the Southeastern of Brazil, triggering the largest outbreak in 
several decades. The outbreak expanded to previously YF-free areas in the neighbor 
States of Espirito Santo, Rio de Janeiro and Sao Paulo, a highly populated area1. 
From December 2016 to July 2017, 777 confirmed human YF cases and 261 deaths 
were reported2. In the following season, from July 1st, 2017 to June 30, 2018, 1,376 
confirmed human YF cases and 483 deaths were registered3. The sylvatic cycle was 
responsible for all human cases, but YF re-urbanization was a concern, due to the 
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great number of human YF cases in large urban centers 
with high densities of Aedes aegypti infestation and low 
YF vaccine coverage4. 
YF vaccination was expanded to the entire population 
living in areas without prior vaccine recommendations, 
in which the outbreaks took place5. The search for the 
YF vaccine has hugely increased in Sao Paulo city, as the 
forests around the State capital have become transmission 
areas. Health services had to attend the population that 
was queuing to receive the vaccine. Those with underlying 
conditions were referred to reference centers to see if they 
could be vaccinated. 
Despite being safe, the YF live attenuated vaccine can 
rarely cause severe illnesses, such as acute neurologic 
disease (0.2 cases per 100,000 doses) or vaccine-
associated viscerotropic disease (YEL-AVD) (0.04 cases 
per 100,000 doses)6,7. Vaccine contraindications include 
children under six months of age, pregnant women, 
immunocompromised persons, those with a history 
of thymus disease, and those who had anaphylactic 
reactions to the vaccine components. Given the high 
risk of YF transmission at that time, panels of experts in 
immunodepression/ immunosuppression conditions and 
vaccinologists standardized YF vaccination criteria for some 
groups of immunocompromised persons, such as those with 
immuno-mediated rheumatic diseases (IMRD)8. 
The aim of this study is to report the adverse events 
following immunization (AEFI) in immunocompromised 




This observational retrospective study was conducted at 
the Reference Center for Special Immunobiologicals (Centro 
de Referencia para Imunobiologicos Especiais – CRIE) 
of the Hospital das Clinicas (HC), a tertiary/quaternary 
hospital attached to the University of Sao Paulo Medical 
School (FMUSP), in Sao Paulo city, from September 2017 
to December 2018. Immunocompromised persons due to 
chronic conditions or immunosuppressive therapy, who 
searched or were referred to the CRIE to receive the YF 
vaccine, were screened by the physicians regarding the 
risks and benefits of their vaccination. The YF vaccine 
recommendation was individualized, taking into account the 
type, severity and activity of the underlying condition and 
the degree of immunosuppression. We used the criteria of 
the Brazilian Society of Rheumatology, Brazilian Society 
of Infectious Diseases and Brazilian Society of Tropical 
Medicine on YF vaccination of patients with IMRD8, to 
recommend the YF vaccination to: clinically stable persons 
with low grade immunosuppression, defined by a single-
drug therapy with: hydroxychloroquine or sulfasalazine 
(any dosage); corticosteroids in prednisone equivalence 
dosage ≤ 2 mg/kg or ≤ 20 mg daily; methotrexate (MTX) ≤ 
0.4 mg/kg or ≤ 20 mg weekly; or leflunomide ≤ 20 mg/day8. 
The YF vaccine was contraindicated for persons taking 
methylprednisolone pulse therapy, mycophenolate 
mofetil, cyclosporine, cyclophosphamide, azathioprine, 
JAK inhibitors, such as tofacitinib, and biological 
immunomodulators8. Whenever other conditions, such 
as chronic kidney and liver diseases, neurologic diseases, 
and cancer were present, YF vaccine recommendations 
were discussed by the CRIE staff with experts of the HC. 
The YF vaccination was recommended, by the attending 
physicians, for immunocompromised clinically stable 
persons whose exposure was considered high, in such a 
way that the benefits of vaccination were considered to 
outweigh its risks. All vaccinees received a full-dose of YF 
17DD vaccine. They were oriented regarding the AEFI and 
advised to return to the CRIE in such case. Authorization for 
a post-vaccination contact, through phone call or electronic 
message (email, WhatsApp) to assess the AEFI was asked 
for all vaccinees with chronic conditions. 
Local and systemic AEFI were evaluated by a standard 
form, applied by phone call or electronic message. The 
following data was collected: age, underlying conditions, 
drugs in use and adverse events. Solicited AEFI were pain, 
edema and erythema at the injection site, fever, headache 
and myalgia. Unsolicited AEFI were any other events 
reported by vaccinees. AEFI intensity and dates of start and 
end were also collected. Contact with the participants was 
made from 14 to 90 days after vaccination and at least three 
contact attempts were made for each participant. 
This report was approved by the Ethical Committee 




During the study period, 29,595 YF vaccine doses were 
administered at the CRIE. Most vaccinees had no vaccine 
contraindication; 571 persons with chronic conditions, using 
or not immunosuppressive therapy, had a pre-vaccination 
evaluation and 381 (66.7%) of them were vaccinated and 
included in this report (Table 1). 
The vaccinees age ranged from 1.4 to 89.3 years (mean, 
48.6 and median, 50.8 years); 53% of them were women. 
All of them denied prior YF vaccination. Among the 381 
vaccinees, the most common underlying conditions was 
chronic kidney disease (CKD) (178 participants, 46.7%), 
mostly dialytic (79.8%); immune-mediated inflammatory 
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Table 1 - Characteristics of immunocompromised persons screened for the yellow fever (YF) vaccination at the Reference Center for 
Immunobiologicals (CRIE) of Hospital das Clinicas of University of Sao Paulo Medical School, from September 2017 to December 
2018. 
Characteristics YF vaccine was not 
recommended (n=190)
YF vaccine was 
recommended (n=381)
Age (years) 
    Min-Max. 
    Median 
    Mean
 




1.4 – 89.3 
50.8 
48.7
Female gender 130 (68.4%) 202 (53.0%)
Underlying conditions
Chronic kidney diseases 
    Dialytic 
    Non-dialytic 









Immune-mediated inflammatory diseases 
    Rheumatoid Arthritis 
    Systemic Lupus Erythematosus 
    Sjogren’s syndrome   
    Ankylosing spondylitis 
    Mixed connective tissue disease 
    Inflammatory bowel disease  
    Psoriasis 
    Scleroderma 
    Cutaneous lupus 























Diabetes mellitus 11 (5.8%) 58 (15.2%) 
Adrenal insufficiency 13 (6.8%) 41 (10.8%) 
Neoplasia  
    Hematological 




18 (4.7%)  
12** 
  6
Chronic liver diseases 
   Cirrhotic  




17 (4.5%)  
13  
4
HIV 11 (5.8%) 16 (4.2%) 
Neurological diseases 
    Multiple sclerosis 
    Muscular dystrophy 









Chronic lung diseases 2 4 
Cardiac insufficiency 1 3







Solid organ transplantation 





Frailty syndrome 2 2
Addison 2 0
Pregnancy 2 0
Egg or erythromycin allergy 1 7
Neurological events following other vaccines (ADEM – 
MMR, GBS – Flu)
0 2
Other conditions*** 5 12
Use of  immunosuppresssors 111 (58.4%) 94 (24.7%)
*Other autoimmune diseases – Antiphospholipid syndrome, Behcet’s disease, Systemic sclerosis, Dermatomyositis, Lichen 
planus, Pemphigus, Autoimmune hepatitis, Grave’s disease, Hashimoto’s disease, Takayasu’s arteritis, Temporal arteritis, Celiac 
disease, Osteoarthritis, unspecified rheumatologic diseases; **Chronic myeloid leukemia - 8 (5 using Imatinib, 1 dasatinib); Chronic 
lymphocytic leukemia - 3; Acute lymphocytic leukemia -1; ***Other conditions: Asplenia/Splenectomy, hemangioma, porphyria, 
bullous epidermolysis, chronic urticaria, eczema, Kawasaki syndrome, sarcoidosis, muscular dystrophy, epilepsy, bariatric surgery, 
Bannayan-Rilley-Ruvalcaba syndrome, chronic use of corticoids without diagnosis. 
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disorders (78, 20.5%); primary or secondary adrenal 
insufficiency (41, 10.8%); neoplasms (18, 4.7%); chronic 
liver diseases (17, 4.5%) and HIV/AIDS (16, 4.2%) 
(Table 1). Ten persons living with HIV had CD4 count 
between 200 and 350 cells/mm3 and the other six had 
associated CKD. Several participants had more than one 
chronic condition, such as rheumatoid arthritis and systemic 
lupus erythematosus (SLE) or SLE and CKD. Diabetes 
mellitus was the most frequent associated comorbidity 
(58 participants, 15.2%). Seven persons have also reported 
mild allergy to egg or erythromycin (none of them reported 
anaphylaxis).
Ninety-four vaccinees (24.7%) were using or had recently 
used immunosuppressive and/ or immunomodulatory drugs; 
53 were using corticosteroids and seven were using a 
prednisone equivalence dosage ≥ 20mg/day for more than 
14 days; 16 were taking MTX, of whom four received 
20 mg/week. Two patients used azathioprine but had 
stopped the medication 2-3 months before vaccination, 
and another one was still using it when he was vaccinated 
(50 mg/day; 0.7 mg/kg/day). One vaccinee had stopped 
etanercept 3 months before vaccination, 13 were taking 
chloroquine, five Imatinib, four sulfasalazine or mesalazine, 
three hydroxyurea and one patient was receiving dasatinib 
and omalizumab. Patients with solid organ tumors had 
stopped chemotherapy and/or radiotherapy ≥ 3 months 
before vaccination.
We were able to contact (within three months after 
vaccination) 341 of the 381 vaccinees (89.5%). Amongst 
the 341 contacted vaccinees, 233 (68.3%) received the YF 
vaccine from BioManguinhos (12 different batches were 
used, from 1 to 89 vaccinees by batch) and 108 (31.7%) 
received the YF vaccine from Sanofi-Pasteur (just one 
batch). One hundred and thirty vaccinees (38.1%) received 
other vaccines (up to 4) simultaneously. The following 
vaccines were administered simultaneously: hepatitis B 
(59 vaccines), pneumococcal polysaccharide 23-valent 
(PPV23, 46), influenza (43), diphtheria-tetanus (dT, 41), 
meningococcal C conjugate (MenCc, 22), hepatitis A (7), 
measles-mumps-rubella (MMR, 6), and varicella (7).
Two hundred and thirty (67.5%) vaccinees reported no 
AEFI; 44 (12.9%) presented local AEFI and 79 (23.2%) 
reported systemic AEFI and 12 persons had both local 
and systemic AEFI. The most frequently reported AEFI 
was pain at the injection site (12%), followed by myalgia 
(10%), fever (7.3%) and headache (4.7%) (Table 2). 
Among the 233 persons who received the vaccine from 
BioManguinhos, 74 (31.75%) did not present any AEFI, 
26 (11.15%) had local AEFI and 54 (23.17%) had systemic 
AEFI; whereas among the 108 persons who received 
the vaccine from Sanofi-Pasteur, these features were 
37 (34.25%), 18 (16.66%), and 25 (23.14%), respectively 
(Table 2). AEFI rates did not differ according to the vaccine 
producer (χ2 for any AEFI=0.21, p=0.647).
Local AEFI was significantly more frequently reported 
by persons who received other vaccines simultaneously 
(35/130, 26.9%) as compared to vaccinees that received only 
the YF vaccine (9/201, 4.5%; χ2=34.5056, p< .00001). The 
frequency of systemic AEFI was also higher in persons who 
received other vaccines simultaneously (36/130, 27.7%) as 
compared to vaccinees that received only the YF vaccine 
(40/201, 19.9%), but this difference was not statistically 
significant (χ2=2.7095, p=0.1). Information on other 
vaccines were not available for 10 vaccinees. 
Twelve (3.5%) vaccinees presented a flu-like syndrome, 
defined by fever in addition to headache or myalgia: 
six (2.8%) of these vaccinees received the vaccine from 
BioManguinhos and the other six (5.5%) vaccinated with 
the vaccine from Sanofi-Pasteur. Unsolicited AEFI were 
reported by 36 persons. Asthenia was the most frequent 
unsolicited AEFI (9 vaccinees, 2.6%). The mean time 
between vaccination and symptoms onset was: 3.68 days, 
for headache, 3.54 days for myalgia and 4.3 days for fever.
There were four severe AEFI: one hospitalization took 
place around two weeks after the YF vaccination (vaccine 
from Sanofi-Pasteur) due to dialysis complications, and 
there were three deaths. The death certificates were provided 
by the families to the CRIE staff in all three cases: a 59-year-
old man with dialytic CKD due to diabetes mellitus died 
3 days after vaccination (vaccine from Sanofi-Pasteur) and 
the cause of death was an acute myocardial infarction; a 
38-year-old woman with dialytic CKD due to eclampsia 
died 16 days after vaccination (vaccine from Sanofi-Pasteur) 
from pulmonary thromboembolism; and a 32-year-old man 
with dialytic CKD who presented an acute febrile disease 
that started five days after vaccination (vaccine from 
BioManguinhos) and evolved with septic shock and death 
12 days after vaccination. Pneumococcal endocarditis and 
lung abscesses were observed at autopsy. 
 
DISCUSSION
It is important to point out that vaccination of 
immunocompromised persons, described in this 
observational retrospective study, was conducted during 
an YF outbreak in a previously transmission-free area. 
There was a high pressure for vaccination by both, 
the population and also by physicians who cared for 
immunocompromised patients. The results suggest the 
YF vaccines may be used in mildly immunocompromised 
persons who are clinically stable and live in high-risk 
areas. In this study, most AEFI were mild and resolved 
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Table 2 - Adverse events (AE) following the yellow fever (YF) vaccination reported by 341 immunocompromised persons vaccinated 
with the vaccine from BioManguinhos or the one from Sanofi-Pasteur at the Reference Center for Immunobiologicals (CRIE) of 
Hospital das Clinicas of University of Sao Paulo Medical School, from September 2017 to December 2018.
AE following vaccination






At least one AE 74 (31.8) 37 (34.3) 111 (32.6)
Local AE 26 (11.2) 18 (16.7) 44 (12.9)
Solicited local AE
Pain 23 (9.9) 18 (16.7) 41 (12.0)
Edema 0 5 (4.6) 5 (1.5)
Erythema 2 (0.8) 1 (0.9) 3 (0.9)
Unspecified local AE 1 (0.4) 0 1 (0.3)
Systemic AE 54 (23.2) 25 (23.2) 79 (23.2)
Solicited systemic AE 
Myalgia 24 (10.3) 10 (9.3) 34 (10.0)
Fever 17 (7.3) 8 (7.4) 25 (7.3)
Headache 7 (3.0) 9 (8.3) 16 (4.7)
Unsolicited systemic AE
Asthenia 8 (3.0) 1 (0.9) 9 (2.6)
Somnolence 3 (1.3) 0 3 (0.9)
Nausea/Vomiting 3 (1.3) 0 3 (0.9)
Malaise 2 (0.9) 1 (0.9) 3 (0.9)
Diarrhea 0 2 (1.9) 2 (0.6)
Sore throat  1 (0.4) 1 (0.9) 2 (0.6)
Facial edema** 1 (0.4) 0
Hoarseness 1 (0.4) 0 1 (0.3)
Cough 0 1 (0.9) 1 (0.3)
Jaundice 1 (0.4) 0 1 (0.3)
Papular lesions (on the back of hands and feet) 1 (0.4) 0 1 (0.3)
Arrhythmia 1 (0.4) 0 1 (0.3)
Joint swelling 0 1 (0.9) 1 (0.3)
“Neck heat” 0 1 (0.9) 1 (0.3)
Renal colic 0 1 (0.9) 1 (0.3)
Lower limbs paresthesia 1 (0.4) 0 1 (0.3)
Lymphadenomegaly 1 (0.4) 0 1 (0.3)
Abdominal pain 1 (0.4) 0 1 (0.3)
Pruritus 1 (0.4) 0 1 (0.3)
Chills 1 (0.4) 0 1 (0.3)
Hypertensive episode 1 (0.4) 0 1 (0.3)
Severe AE*** 1 (0.4) 3 (2.8) 4 (1.2)
Hospitalization 0 1 (0.9) 1 (0.3)
Death 1 (0.4) 2 (1.9) 3 (0.9)
*12 vaccinees had both, local and systemic AE. Each vaccinee may have had ≥ 1 symptom; **A boy aged 57 months with history 
of egg allergy had facial edema that regressed with antiallergic drugs; ***None of the severe AEFI was considered related to the 
vaccination. 
spontaneously without complications. Four severe AEFI 
were reported (one hospitalization and three deaths), that 
were considered not related to the YF vaccination. All 
severe AEFIs occurred in patients with dialytic CKD. 
The deaths were considered not related to the YF vaccines 
based on the death certificates that contained well-defined 
causes of death. 
We detected a higher frequency of any of the AEFI 
(32.5%), such as fever (7%) and reactions at the injection site 
(12.9%) after the YF vaccination of immunocompromised 
persons in comparison with the previously reported 
frequencies in immunocompetent persons9. No differences 
on AEFI rates according to the vaccine producer were 
observed. The package insert of the YF vaccine from 
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BioManguinhos states that 2-5% of vaccinees may present 
headache, myalgia, fever and other mild symptoms from 
the 5th to the 10th day following vaccination. The package 
insert of the YF vaccine from Sanofi-Pasteur informs that 
mild injection site reactions, such as erythema and pain, 
and systemic reactions, such as headache and fever, occurs 
typically in less than 5% of vaccinees, 5 to 7 days after 
vaccination. A randomized controlled trial that evaluated 
the YF vaccine from BioManguinhos in adults found that 
up to 20.9% of vaccinees have at least one AEFI9. The most 
frequent AEFI was headache (12.8%), followed by flu-like 
syndrome, defined as myalgia associated with headache and 
fever (7.1%), and myalgia (6.7%); injection site reactions 
were reported by 3.3%, and fever and nausea by 3% each9. 
According to WHO, “in clinical trials, mild adverse events, 
such as headache, myalgia, low-grade fever, discomfort at 
the injection site, pruritus, urticaria and rash were reported 
by up to 25% of vaccinees”10. 
Simultaneous vaccination, administered to 38.1% 
of persons in this study, may increase AEFI rates. In 
addition, local AEFIs were statistically associated with 
multiple vaccinations. Persons with chronic conditions/ 
immunocompromised are commonly unaware of 
recommended vaccines for their health conditions. In the 
healthcare practice, we take advantage of every visit to the 
vaccine room to update the immunization. Most AEFIs are 
mild and self-limited and should not be a reason to withhold 
multiple vaccinations when they are needed.
There are few reports of YF vaccination in 
immunocompromised persons in the literature, most of 
them retrospective studies describing the inadvertent 
vaccination of only a few persons. Available data on the 
YF vaccine safety in this group is very scarce and potential 
risks are serious, including death. There is a report of fatal 
encephalitis following the YF vaccination in a person 
with asymptomatic HIV unaware of his condition11. A 
Brazilian study involving 70 rheumatic patients using 
immunosuppressors reported 16 (22.9%) minor AEFIs. 
Among eight patients using immunobiological agents, only 
one presented a mild AEFI12. Another study described the 
YF vaccination in 17 patients with rheumatoid arthritis 
receiving infliximab and MTX. No AEFI was observed, but 
all the vaccinees had received a previous YF vaccine dose ≥ 
10 years before and most of them (10/12) were seropositive 
before revaccination13. A systematic review to access the 
safety of live vaccines in patients with immune-mediated 
inflammatory diseases or solid organ transplantation on 
immunosuppressive treatment and hematopoietic stem-cell 
transplantation included 64 articles that reported 253 
administered YF vaccine doses. A patient with rheumatoid 
arthritis and systemic lupus erythematosus (SLE), who 
started MTX/ dexamethasone treatment four days after the 
YF vaccination had YEL-AVD and died14. There are several 
reports of YEL-AVD in persons with immune-mediated 
inflammatory diseases, particularly SLE6,15. The potential 
risk of severe AEFIs in this population is not known and 
vaccines should be used only in high risk situations, 
preceded by a careful individual screening. 
A French study interviewed 34 adult travelers who 
had received the YF 17D vaccine while on systemic 
corticosteroid therapy (median duration, 10 months; 
prednisone equivalent dosage, 7 mg/day). No serious 
AEFI was reported, but they have also found that 
vaccinees receiving corticosteroids reported more frequent 
moderate/severe local reactions (12%) than controls 
(2%)16. A study conducted in travel clinics in Zurich 
retrospectively identified and interviewed 116 travelers on 
immunosuppressive/ immunomodulatory therapy who had 
received live attenuated vaccines; 92 doses of YF vaccine 
were administered17. A patient with rheumatoid arthritis 
using sulfasalazine reported severe myalgia and arthralgia 
after the YF vaccination17.
A cross-sectional study assessed the YF vaccination 
among 130 patients with dialytic CKD; 45 patients received 
the YF vaccine, of whom 21 had never been vaccinated 
before18. AEFI were reported by 26.7% (12/45) vaccinees, 
with mild local AEFI in 11 (24.4%). Two patients had fever, 
which resolved in 24 h. No serious AEFI was reported17,18. 
Another study retrospectively identified 19 solid organ 
transplanted patients who inadvertently received the YF 
vaccine and one of them reported mild reaction at the 
injection site and none reported systemic AEFI19. However, 
cases series that retrospectively identified vaccinees among 
patients in follow-up may not be able to identify deaths 
related to serious AEFI.
The present study has limitations. This is an observational 
study, but considering the YF vaccine contraindication 
for immunocompromised persons, it will be considered 
for this population only in high-risk settings, such as 
outbreaks/epidemics, when a controlled trial would not be 
possible/ethical. The decision on vaccinating (or not) an 
individual was taken in the care practice by five attending 
physicians and, although we have tried to standardize the 
recommendations/contraindications, differences among 
their conducts may have happened. Furthermore, we 
evaluated several different conditions and drugs that make 
their individual analysis not feasible. Finally, our sample 
size was small, inappropriate to evaluate rare events and we 
were not able to contact 10.5% of the vaccinees. However, 
the vaccinees were oriented regarding possible AEFI and 
advised to return to the service in case of AEFI, and we 
contacted them in a short period of time after vaccination 
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(15-90 days) making it easier for them to remember AEFIs.
This study was carried out during an outbreak of YF, 
with great stress, due to both, the demand for the vaccine 
and the fear of YF urbanization. New prospective studies 
with specific populations, larger sample sizes, including 
viremia assessment and healthy controls are needed. Even 
though, we believe that our results allow us to conclude 
that the YF vaccine may be administered to mildly 
immunocompromised, clinically stable persons living in 
high-risk areas, always preceded by a careful individual 
assessment, weighing the benefits and risks of vaccination.
ACKNOWLEDGMENTS
We thank the entire CRIE staff for supporting this work. 
AUTHORS’ CONTRIBUTIONS
ANL, AMCS: literature search, tables, data collection, 
writing, revision; KTM: data collection, revision; KYI, 
MHL: data collection, revision.
REFERENCES
 1. Possas C, Lourenço-de-Oliveira R, Tauil PL, Pinheiro FP, 
Pissinatti A, Cunha RVD, et al. Yellow fever outbreak in 
Brazil: the puzzle of rapid viral spread and challenges for 
immunisation. Mem Inst Oswaldo Cruz. 2018;113:e180278.
 2. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. 
Emergência epidemiológica de febre amarela no Brasil, no 
período de dezembro de 2016 a julho de 2017. Bol Epidemiol. 
2017;48:1-22.
 3. Brasil. Ministério da Saúde. Informe Nº27: monitoramento do 
período sazonal da febre amarela: Brasil – 2017/2018. [cited 
2020 Oct 14] Available from: https://portalarquivos2.saude.
gov.br/images/pdf/2018/outubro/08/Informe-FA.pdf
 4. Cavalcante KR, Tauil PL. Risk of re-emergence of urban yellow 
fever in Brazil. Epidemiol Serv Saude. 2017;26:617-20.
 5. World Health Organization. Yellow fever: Brazil. [cited 2020 
Oct 14]. Available from: http://who.int/csr/don/04-april-2017-
yellow-fever-brazil/en/
 6. Martins RM, Maia ML, Santos EM, Cruz RL, Santos PR, Carvalho 
SM, et al. Yellow fever vaccine post-marketing surveillance in 
Brazil. Procedia Vacinnol. 2010;2:178-83.
 7. Seligman SJ. Risk groups for yellow fever vaccine-associated 
viscerotropic disease (YEL-AVD). Vaccine. 2014;32:5769-75.
 8. Sociedade Brasileira de Reumatologia. Sociedade Brasileira 
de Infectologia. Sociedade Brasileira de Medicina Tropical. 
Nota técnica conjunta sobre vacinação para a febre amarela 
(VFA) em pacientes com doenças reumáticas imunomediadas 
(DRIM). [cited 2020 Oct 14]. Available from: https://
www.reumatologia.org.br/downloads/pdf/nota-sociedades-
vacina%C3%A7%C3%A3o-febre-amarela-2018.pdf 
 9. Camacho LA, de Aguiar SG, Freire MS, Leal ML, do Nascimento 
JP, Iguchi T, et al. Reactogenicity of yellow fever vaccines in 
a randomized, placebo-controlled trial. Rev Saude Publica. 
2005;39:413-20.
 10. World Health Organization. Vaccines and vaccination against 
yellow fever. WHO position paper - June 2013. Wkly 
Epidemiol Rec. 2013;88:269-83.
 11. Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal 
myeloencephalitis following yellow fever vaccination in a case 
with HIV infection. J Med Assoc Thai. 2002;85:131-4.
 12. Mota LM, Oliveira AC, Lima RA, Santos-Neto LL, Tauil PL. 
Vacinação contra febre amarela em pacientes com diagnósticos 
de doenças reumáticas, em uso de imunossupressores. Rev Soc 
Bras Med Trop. 2009;42:23-7.
 13. Scheinberg M, Guedes-Barbosa LS, Mangueira C, Rosseto 
EA, Mota L, Oliveira AC, et al. Yellow fever revaccination 
during infliximab therapy. Arthritis Care Res (Hoboken). 
2010;62:896-8.
 14. Croce E, Hatz C, Jonker EF, Visser LG, Jaeger VK, Bühler S. 
Safety of live vaccinations on immunosuppressive therapy in 
patients with immune-mediated inflammatory diseases, solid 
organ transplantation or after bone-marrow transplantation: a 
systematic review of randomized trials, observational studies 
and case reports. Vaccine. 2017;35:1216-26.
 15. Seligman SJ. Yellow fever virus vaccine-associated deaths in 
young women. Emerg Infect Dis. 2011;17:1891-3.
 16. Kernéis S, Launay O, Ancelle T, Iordache L, Naneix-Laroche 
V, Méchaï F, et al. Safety and immunogenicity of yellow 
fever 17D vaccine in adults receiving systemic corticosteroid 
therapy: an observational cohort study. Arthritis Care Res 
(Hoboken). 2013;65:1522-8.
 17. Huber F, Ehrensperger B, Hatz C, Chappuis F, Bühler S, 
Eperon G. Safety of live vaccines on immunosuppressive or 
immunomodulatory therapy: a retrospective study in three 
Swiss travel clinics. J Travel Med. 2018;25:tax082.
 18. Facincani T, Guimarães MN, Santos SS. Yellow fever vaccination 
status and safety in hemodialysis patients. Int J Infect Dis. 
2016;48:91-5.
 19. Azevedo LS, Lasmar EP, Contieri FL, Boin I, Percegona L, 
Saber LT, et al. Yellow fever vaccination in organ transplanted 
patients: is it safe? A multicenter study. Transpl Infect Dis. 
2012;14:237-41.
